Gastrointestinal disorders as immune-related adverse events

Exploration of Targeted Anti-tumor Therapy

Antonio Benedetti¹  Luca Maroni¹  Daniele Balducci¹  Claudia Quatraccioni¹  Marco Marzioni¹ 

[1] Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti-University Hospital, 60126 Ancona, Italy;

关键词: cytotoxic t-lymphocyte antigen 4;    programmed cell death 1;    programmed cell death-ligand 1;    immune checkpoint;    gastrointestinal toxicity;   

DOI  :  10.37349/etat.2021.00039

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results and an increase in survival rates. However, immune-related adverse events (irAEs) are frequent and often require special care. IrAEs may affect all the organs, but they are most commonly seen in skin, lungs, endocrine glands and in the gastrointestinal tract where small bowel, colon, the liver and/or the pancreas can be involved. Despite being usually mild and self-resolving, irAEs may present in severe and life-threatening forms, causing the withdrawal of anti-cancer therapy. IrAEs, therefore, represent a challenging condition to manage that often requires the cooperation between the oncologists and the gastroenterologists in order to identify and treat them adequately.

【 授权许可】

Unknown